SF3B1 and hematopoietic and lymphoid system neoplasm: Previous studies reported that disrupted splicing due to SF3B1 or U2AF1 mutation involves hematopoietic malignancy, HM, and heme biosynthesis in MDS or other blood cancers [47], [48], [49], [50], [51], [52], [53].